Shares of Aurora Cannabis (NYSE:ACB,TSX:ACB) continued to take a beating on Monday (November 18) after the firm announced it is halting the construction of two of its planned facilities to save a total of C$190 million.
Aurora has dropped 29.9 percent since market close on Thursday (November 14), the day it released its most recent quarterly results; it sat at C$3.07 as of 2:44 p.m. EST on Monday.
In its results for its first fiscal quarter of 2020, the Edmonton-based company confirmed it will be stopping construction of its Aurora Nordic 2 facility in Denmark to save C$80 million over the next year.
The company also said it will be indefinitely deferring construction of its Aurora Sun facility in Medicine Hat, Alberta, and will conserve C$110 million in the process.
Aurora Sun was slated to be a 1.2 million square foot facility in the firm’s home province when it was first announced in 2018, and would have brought Aurora’s yearly cultivation capacity to 430,000 kilograms.
The first planting was planned for the first half of 2019, Aurora initially said, and the facility was set to be completed during the second half of this year. Aurora told investors this week that it still expects to have at least six flower rooms totaling 238,000 square feet completed and operating by 2020.
“As global demand develops, or as Aurora’s market share in the global cannabis market increases, we will reactivate these projects,” the company said in a statement.
Aurora is the latest marijuana company to be forced to halt current projects due to cautionary spending tactics in response to current market conditions. HEXO (NYSE:HEXO,TSX:HEXO) also announced it will be suspending activities for the entirety of its facility in Niagara, Ontario, and 200,000 square feet of its facility in Gatineau, Quebec.
Aurora CFO Glen Ibbott said during a call with analysts last week that construction adjustments for both facilities are an effort to more closely align timelines with increasing demand for product.
“These adjustments will result in a significant decrease in our ongoing quarterly level of capital investment,” said Ibbott.
The construction freezes come after the company announced a drop of 24 percent in total net revenue in the latest quarter. It sank to C$75.2 million from C$98.9 million in Aurora’s fourth fiscal quarter of 2019.
Aurora attributed the loss to a decrease in revenue of non-wholesale cannabis and a slowdown of consumer cannabis sales as distributors worked through an inventory surplus over the summer. The firm also mentioned the slow retail store rollout as an inhibitor to revenue generation this quarter.
“The past few months have been challenging for the broader cannabis industry. Between issues of governance, evolving consumer demand and provincial retail bottlenecks, there has been no shortage of negative news,” said Chief Corporate Officer Cam Battley during the call.
He added that the company is still optimistic about the Canadian and international cannabis markets.
Aurora’s revenues missed the mark for analyst expectations. According to financial market data firm Refinitiv, analysts projected C$93.31 million in revenue for this past quarter.
The firm also reported a reduction in production cash cost to C$0.85 per gram, down from C$1.14 per gram in the previous quarter, as well as a cannabis yield of 41,436 kilograms, up 43 percent quarter-on-quarter from 29,034 kilograms.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).